


Scythian Biosciences appoints new CEO

04 October 2018 | News

Cobb replaces Rob Reid, who has stepped down to focus on European Cannabis Investment opportunities.



Singapore - Scythian Biosciences announced Brady Cobb, a leading voice in the medical cannabis industry, has been appointed Chief Executive Officer. Effective October 3, 2018, Mr. Cobb replaces Rob Reid, who has stepped down to focus on European Cannabis Investment opportunities and will remain as an active member of the Board of Directors and key person in driving the company's strategic direction.

"I am extremely grateful to have served Scythian and proud of what our team has accomplished," said Rob Reid. "I will be stepping down with nothing but appreciation and admiration for my colleagues as I shift my focus to European Cannabis Investment opportunities."

In addition, the Company has named Chairman Andy DeFrancesco to the position of Chief Investment Officer effective November 1, 2018. In this role, Andy will continue driving Scythian's strategic plan through identifying and evaluating expansion opportunities accretive to the company's existing holdings throughout the United States and beyond to ensure further value creation and growth in stockholder value.

Mr. Cobb formed a strategic relationship with the BGR Group, a Washington, D.C.-based government relations firm headed by former Mississippi Governor Haley Barbour. Working with BGR, Mr. Cobb has been a proponent of the Rohrabacher-Leahy amendment to the 2018 Congressional omnibus appropriations bill, which affords protections to the medical cannabis market from Department of Justice enforcement.

Mr. Cobb was Chief Legal Officer for Liberty Health Sciences through July 2018, and has owned and operated his South Florida based boutique business and governmental relations law firm since 2012.